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The antiproliferative action of the retinoblastoma tumor suppres-
sor protein, RB, is disrupted in the majority of human cancers.
Disruption of RB activity occurs through several disparate mecha-
nisms, including viral oncoprotein binding, deregulated RB phos-
phorylation, and mutation of the RB gene. Here we report disrup-
tion of RB-signaling in tumor cells through loss of a critical coop-
erating factor. We have previously reported that C33A cells fail to
undergo cell cycle inhibition in the presence of constitutively active
RB (PSM-RB). To determine how C33A cells evade RB-mediated
arrest, cell fusion experiments were performed with RB-sensitive
cells. The resulting fusions were arrested by PSM-RB, indicating
that C33A cells lack a factor required for RB-mediated cell cycle
inhibition. C33A cells are deficient in BRG-1, a SWIySNF family
member known to stimulate RB activity. Consistent with BRG-1
deficiency underlying resistance to RB-mediated arrest, we iden-
tified two other BRG-1-deficient cell lines (SW13 and PANC-1) and
demonstrate that these tumor lines are also resistant to cell cycle
inhibition by PSM-RB and p16ink4a, which activates endogenous
RB. In cell lines lacking BRG-1, we noted a profound defect in
RB-mediated repression of the cyclin A promoter. This deficiency in
RB-mediated transcriptional repression and cell cycle inhibition
was rescued through ectopic coexpression of BRG-1. We also
demonstrate that 3T3-derived cells, which inducibly express a
dominant-negative BRG-1, arrest by PSM-RB and p16ink4a in the
absence of dominant-negative BRG-1 expression; however, cell
cycle arrest was abrogated on induction of dominant-negative
BRG-1. These findings demonstrate that BRG-1 loss renders cells
resistant to RB-mediated cell cycle progression, and that disruption
of RB signaling through loss of cooperating factors occurs in cancer
cells.
cyclins u Cdk u SWIySNF
The retinoblastoma tumor suppressor protein (RB) is a criticalregulator of cell cycle progression that is functionally inac-
tivated in the majority of human tumors (1–8). RB functions as
a protein-binding protein, binding to greater than 50 identified
cellular proteins. However, the requirement of these proteins for
RB-mediated cell cycle inhibition is largely unknown. Overall,
RB-assembled protein complexes lead to the repression of
transcription, and this function of RB is critical for cell cycle
regulation. The principal target of RB is believed to be the E2F
family of transcriptional activators (6, 9–11). E2F controls the
expression of numerous genes directly involved in cell cycle
progression or in metabolic processes coupled to DNA replica-
tion (6, 9–11). RB binding converts E2F from a transcriptional
activator to a repressor through a mechanism that involves the
recruitment of histone deacetylases (12, 13). RB also mediates
the repression of other gene products, such as cyclin A, through
complicated mechanisms that are not clearly understood (14).
In response to mitogenic signaling, RB is phosphorylated in
mid-G1 by Cdk4ycyclin D complexes (1–4). This initial phos-
phorylation contributes to the disruption of RB protein-binding
activity, thus alleviating RB-mediated transcriptional repression
(15). RB is the only relevant target for Cdk4ycyclin D, as
inhibition of Cdk4 results in cell cycle arrest only in those cells
that express a functional RB protein (16–18). Later in G1,
Cdk2ycyclin E, and cyclin A complexes also phosphorylate RB
(1–4). However, unlike Cdk4ycyclin D, Cdk2 complexes are
required for cell cycle progression in the absence of RB (19, 20).
Together, Cdk4 and Cdk2 complexes are required and are rate
limiting for cell cycle progression (20).
The mechanism through which RB acts on the cell cycle has
been difficult to address, because it is rapidly phosphorylat-
edyinactivated by endogenous Cdk4 and Cdk2 activities (21–24).
To circumvent this difficulty, we generated phosphorylation site
mutants of RB (PSM-RB), which render it insensitive to Cdk-
mediated inactivation (22). Unlike wild-type RB, PSM-RB
overexpression arrests the vast majority of tumor cell lines
studied, confirming that RB phosphorylation is generally re-
quired for progression through the cell cycle (25). Typically, this
RB-mediated cell cycle arrest involves the attenuation of cyclin
A expression and Cdk2-associated kinase activity, whereas Cdk4,
cyclin D1, and cyclin E are unaffected (14, 18, 23). The impor-
tance of cyclin A as a target of RB is exemplified by the
observation that ectopic cyclin A expression overcomes PSM-
RB-mediated cell cycle arrest (14, 26).
Surprisingly, we identified a cell line, C33A, which was resis-
tant to PSM-RB (25). Therefore, this cell line can progress
through the cell cycle in the absence of RB phosphoryla-
tionyinactivation. We hypothesized that C33A cells either har-
bor a dominant activity that inactivates RB or lack a cooperating
recessive activity required for RB function. Although there are
numerous proteins that disrupt RB function (SV40 T-antigen,
adenovirus E1A, E2F-1, cyclin E), few have been shown to
cooperate with RB (1–4). Prior studies demonstrated that
BRG-1, a member of the SWIySNF chromatin remodeling
complex, interacts with RB, and ectopic expression of BRG-1
was shown to cause growth inhibition dependent on interaction
with RB (27–32). Furthermore, it was shown that expression of
BRG-1 enhances RB-mediated inhibition of E2F transcription
(31). These studies suggested that overproduction of BRG-1 can
cooperate with RB. Here, we report that BRG-1 is in fact
required for RB-mediated signaling to critical downstream ef-
fectors and subsequent cell cycle arrest. Moreover, we demon-
strate that loss of BRG-1 function in tumor cells renders them
resistant to the antiproliferative activity of RB, thus revealing a
new mechanism by which tumor cells attain growth advantage.
Materials and Methods
Cells, Plasmids, and Transfection. C33A, SAOS-2, U2OS, SW13,
PC3, and PANC-1 cells were cultured as previously described
(25). B05–1 cells were grown in DMEM supplemented with 10%
heat inactivated calf serum, 100 unitsyml penicillin–streptomy-
cin, and 2 mM L-glutamine either in the presence or absence of
Abbreviation: b-gal, b-galactosidase.
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2 mgyml tetracycline (33). To generate antibiotic resistant lines,
C33A and SAOS-2 cells were transfected with pBabe-Puro or
CMV-NEO, as previously described (34). Selection was carried
out with 2.5 mgyml puromycin or 600 mgyml G418. The follow-
ing plasmids, CMV-NEO, 2608CycALuc, E2FyLuc, pH2B-
GFP, pBabe-Puro, PSM-RB, p27kip1, and p16ink4a, have been
previously described (22, 25, 35).
Cell Fusions. Approximately 3 3 105 drug-resistant C33A and
SAOS-2 cells were combined in a 50-ml conical tube, centrifuged
at 1,000 3 g, resuspended in 5 ml DMEM, and then centrifuged
at 1,000 3 g. The cells were resuspended in 1 ml of fusion buffer
(50% polyethylene glycol 1450 and 50% DMEM) and incubated
for 1 min at room temperature. The cells were then washed in
10 ml of DMEM and plated. After fusion, both puromycin and
G418 were added to the growth media.
Immunoblotting. Approximately 1 3 106 cells were plated in
10-cm dishes 24 h before transfection. Cells were cotransfected
with effectors and either a puromycin selectable plasmid or the
H2B-GFP expression plasmid. Transfected cells were subse-
quently selected with puromycin or sorted by using a fluores-
cence-activated cell sorter. Immunoblotting was carried out by
using standard procedures with the following antibodies: against
Cdk2, cyclin A, cyclin E, Cdk4 (Santa Cruz Biotechnology)
anti-Flag (Zymed), anti-p53 (K. Fukasawa, University of Cin-
cinnati, Cincinnati, OH), anti-vimentin (W. Ip, University of
Cincinnati), and anti-BRG-1 (W. Wang, National Institutes of
Health, Bethesda, MD).
Reporter Assays, BrdUrd Incorporation, and Flow Cytometry. Re-
porter assays, BrdUrd incorporation, and flow cytometry were
performed as previously described (14, 23).
Results
Generation and Characterization of Somatic Cell Fusions. It has been
hypothesized that all cells, including tumor cells, must inactivate
RB to traverse the G1yS transition (1–4). We have previously
reported that whereas the vast majority of tumor cell lines are
arrested by introduction of constitutively active RB (PSM-RB),
C33A (HPV-negative cervical carcinoma) cells are resistant to
PSM-RB-mediated arrest (25). Presumably, a protein that inac-
tivates RB could be responsible for the resistance of C33A cells.
Alternatively, C33A could fail to undergo RB-dependent arrest
because of the loss of a critical RB cofactor. To delineate
between these possibilities, somatic cell fusion experiments were
performed. As summarized in Fig. 1A, C33A cells were fused to
SAOS-2 (osteosarcoma) cells, which we have previously dem-
onstrated to be sensitive to PSM-RB-mediated cell cycle inhi-
bition (25). Initially, stable neomycin and puromycin drug-
resistant populations of both C33A and SAOS-2 cells were
generated and pooled. Resulting drug-resistant cells were then
fused by using polyethylene glycol to generate ‘‘homofusions’’ of
C33A cells (C-C) or SAOS-2 cells (S-S) and ‘‘heterofusions’’ of
C33A with SAOS-2 (C-S) (Fig. 1 A). The fusion populations were
propagated in the presence of dual (puromycin-G418) selection
for 2 weeks, at which point all unfused cells where killed by either
G418 or puromycin (not shown). Giemsa staining of the fused
cells revealed that the homofusions were slightly larger than
parental cells but maintained similar morphologies (Fig. 1B).
Fig. 1. Fusion of RB-resistant to RB-sensitive cells. (A) Cell fusion schema. (B) Parental C33A and SAOS-2 cells, as well as the C-C, S-S, and C-S fusions were fixed
and stained with Giemsa. (C) The fused and nonfused parental cells were lysed, and equal total protein was resolved by SDSyPAGE then immunoblotted for p53
and vimentin. (D) Fused and nonfused parental cells were fixed and then coimmunostained for vimentin and p53. (E) Proliferating fused and nonfused cells were
trypsinized, fixed, and then stained with propidium iodide. The DNA content of the stained cells was then determined by flow cytometry.








However, the heterofusion cells resulted in a large cell with
SAOS-2-like morphology (Fig. 1B). To ensure that the hybrid
cells represent faithful fusion of their parental counterparts,
biochemical analyses were performed. As shown in Fig. 1C,
immunoblot analysis revealed that the mutated form of the
nuclear p53 tumor suppressor gene (expressed only in C33A
cells, lane 1) and the cytoskeletal protein vimentin (found only
in SAOS-2 cells, lane 2) were both expressed in the C-S
populations (lanes 3–6) (36, 37). Immunohistochemistry also
revealed that the homofusions of the parental cells (C-C, S-S)
were not affected in their ability to express p53 (99%) and
vimentin (100%), respectfully (Fig. 1D). Virtually 100% of C-S
fusions expressed both p53 and vimentin, indicating successful
fusion of C33A to SAOS-2. Lastly, the fused cells were analyzed
by flow cytometry, which revealed that both the homofusions as
well as the heterofusions maintained a G1 DNA content of 4N,
whereas the parental cells demonstrated 2N DNA content (Fig.
1E). Four independent C-S fusion populations were generated,
and C-S fusions nos. 1–4 all behaved identically (data not
shown). Thus, the data for C-S fusion no. 1 is representative of
the polyclonal fusion populations. Together, these data affirm
the generation of valid C33A-SAOS-2 heterofusions.
Restoration of RB Signaling to Cyclin A Is Stimulated by Dominant
Genetic Factors. The repression of E2F-mediated transcription is
thought to underlie RB-mediated cell cycle arrest (1). We
therefore examined the effect of PSM-RB on E2F activity in the
fused cells. Interestingly, ectopic expression of PSM-RB in the
C-C, S-S, and C-S fusions resulted in the inhibition of E2F
reporter activity by 71.5%, 92.8%, and 71%, respectively, com-
pared with cells transfected with empty vector (Fig. 2A). These
data demonstrate that RB retains the ability to inhibit E2F
activity in C33A cells, but this inhibition is not sufficient to
induce cell cycle arrest (38). Previous reports have shown that
the ability of RB to signal to attenuate cyclin AyCdk2 activity is
essential for arresting cells at the G1yS transition (14, 23, 38). We
therefore investigated the effect of PSM-RB on the cyclin A
promoter (Fig. 2B). For these experiments, PSM-RB expression
plasmid or parental vector was cotransfected with a human cyclin
A reporter (2608cycAyLuc) plasmid into C-C, S-S, and C-S
cells. Expression of PSM-RB in the C-C hybrid did not affect
cyclin A-dependent transcriptional activity (Left), whereas in the
S-S line, expression of PSM-RB inhibited cyclin A reporter
activity by 94.6% when compared with vector (Center). In the
C-S hybrid lines, expression of PSM-RB inhibited cyclin A
transcriptional activity by 86.2% when compared with vector
(Right). These data demonstrate that SAOS-2 cells contain a
trans-acting factor capable of restoring RB-mediated signaling to
the cyclin A promoter in C33A cells.
To confirm these observations, the effect of RB on endoge-
nous G1 Cdkycyclin expression was determined. The C-C, S-S,
and C-S cell lines were cotransfected with parental vector or
PSM-RB expression plasmid and a histone-H2B-GFP expression
plasmid. Transfected cells were specifically isolated by fluores-
cence-activated cell sorting, and visual immunofluorescence
microscopy revealed .90% GFP-positive cells after sorting
(data not shown). Collected cells were lysed and subjected to
immunoblot analyses (Fig. 2C). Expression of PSM-RB in the
C-C cell line had no effect on the levels of endogenous cyclin A
or Cdk2 protein compared with cells transfected with parental
vector (compare lanes 1 and 2). In S-S cells, ectopic expression
of PSM-RB caused a decrease in both endogenous cyclin A and
Cdk2 protein (compare lanes 3 and 4). Consistent with data from
the reporter assays (Fig. 2B), transfection of PSM-RB caused an
inhibition in cyclin A protein levels in the C-S heterofusions
(compare lanes 5 and 6). PSM-RB also caused a modest reduc-
tion in the levels of Cdk2 protein (compare lanes 3 and 4 and
lanes 5 and 6). In all cells tested, no changes were observed on
PSM-RB transfection in the levels of cyclin E (data not shown)
or Cdk4 (lanes 1–6). Collectively, these data demonstrate that
RB signaling to Cdk2ycyclin A is disrupted in C33A cells
because of the lack of a specific trans-acting factor, which can be
supplied by SAOS-2 cells to restore this signaling pathway.
Because cyclin A is a critical target in RB-mediated arrest,
restoration of RB signaling to cyclin A should restore RB-
mediated cell cycle inhibition in C33A cells. To examine this,
C-C, S-S, and C-S cells were cotransfected with plasmids en-
coding H2B-GFP and either empty vector or PSM-RB and
scored for the ability of transfected (GFP-positive) cells to
incorporate BrdUrd (Fig. 2D). C-C cells transfected with
PSM-RB were not inhibited in their ability to enter DNA
synthesis as compared with untransfected (GFP-negative) cells
from the same coverslip or cells transfected with vector alone
(Left). By contrast, BrdUrd incorporation was abolished in S-S
cells transfected with PSM-RB (Center). The C-S fusion cells
transfected with PSM-RB also failed to incorporate BrdUrd
(Right), consistent with the hypothesis that SAOS-2 cells provide
a dominant trans-acting factor that restores RB activity.
It has been previously shown that ectopic overexpression of
BRG-1, a SWIySNF family member, can enhance RB function
(30–32, 38, 39). C33A cells are reported to be deficient in BRG-1
(30). Therefore, we attempted to restore RB activity in C33A
cells by coexpression of PSM-RB with BRG-1 (Fig. 2E). C-C
cells were cotransfected with H2B-GFP and BRG-1, PSM-RB,
or empty vector. All transfected cells incorporated BrdUrd at
similar rates. However, coexpression of both PSM-RB and
BRG-1 in the C-C fusion resulted in a 62% inhibition of BrdUrd
Fig. 2. A dominant genetic determinant is important for RB signaling. (A)
The C-C, S-S, and C-S cell fusions were transfected with the E2F promoter
reporter plasmid E2FyLuc, CMV-b-galactosidase (b-gal), and vector or PSM-
RB. (B) The C-C, S-S, and C-S cell fusions were transfected with the cyclin A
promoter reporter plasmid 2608Luc, CMV-b-gal, and either vector or PSM-RB.
(C) Fusion cells were cotransfected with H2B-GFP and either CMVNeoBam
(lanes 1, 3, and 5) or PSM-RB (lanes 2, 4, and 6). Forty-eight hours after
transfection, the transfected cells were sorted from the untransfected cells by
fluorescence-activated cell sorting for GFP fluorescence. Lysates were pre-
pared from these cells, and protein was resolved by SDSyPAGE and then
immunoblotted for cyclin A, Cdk2, cyclin E, and Cdk4 proteins. (D) The C-C, S-S,
and C-S cell fusions were cotransfected with a H2B-GFP expression plasmid and
either vector or PSM-RB. BrdUrd was added 48 h after transfection and cells
stained for BrdUrd incorporation. The displayed values were determined from
two independent experiments with at least 150 transfected (GFP positive;
solid bars) or 150 untransfected (GFP negative; open bars) cells counted per
experiment. (E) The C-C cell fusions were cotransfected with H2B-GFP expres-
sion plasmid and either BRG-1 or PSM-RB 1 BRG-1.
7750 u www.pnas.org Strobeck et al.
incorporation. These data demonstrate that like fusion with
SAOS-2, BRG-1 can restore RB activity in C33A cells. Because
SAOS-2 cells express functional BRG-1, we hypothesized that
BRG-1 is the dominant factor present in SAOS-2, which restores
RB activity in C-S cells. This hypothesis predicts that BRG-1 loss
disrupts the antiproliferative action of RB.
BRG-1 Mediates RB Signaling to Cyclin A to Induce Cell Cycle Arrest.
To determine whether loss of BRG-1 in tumor cells disrupts the
ability of RB to inhibit cell cycle progression, a panel of tumor
cell lines were screened for their relative expression of BRG-1.
Consistent with previous reports, BRG-1 protein expression is
dramatically reducedyabsent in C33A and SW13 cells (Fig. 3A)
(30). The PANC-1 cell line expressed considerably reduced
levels of BRG-1, relative to the majority of tested cell lines.
Greater than 20 additional cell lines were clearly positive for
BRG-1, for six of which data are shown (MCF-7, U87, PC3,
SAOS-2, U2OS, and RD). These cells have been previously
tested for their ability to incorporate BrdUrd after transfection
with either empty vector or PSM-RB (25). All BRG-1-positive
cells tested were significantly inhibited (69–97%) for BrdUrd
incorporation after transfection with PSM-RB (Fig. 3B Left).
Strikingly, however, BRG-1-deficient cells (C33A, SW13, and
PANC-1) were not efficiently inhibited for BrdUrd incorpora-
tion (0–21%) after transfection with PSM-RB (Fig. 3B Left).
As described above, the downstream target of RB-mediated
arrest is Cdk2ycyclin A. To determine whether BRG-1-defective
cells still require Cdk2 function for cell cycle progression, SW13
cells were transfected with plasmids encoding H2B-GFP and
either p16ink4a, PSM-RB, or p27Kip1, and scored for the ability
to incorporate BrdUrd (Fig. 3B Center and Right). SW13 cells
continued to incorporate BrdUrd after transfection with either
vector, p16ink4a (which activates the endogenous RB), or PSM-
RB. By contrast, cells transfected with p27Kip1, which is a direct
inhibitor of Cdk2, were inhibited for BrdUrd incorporation, and
similar results have been observed in C33A cells (38, 39).
Therefore, the requirement for Cdk2 is maintained in BRG-1-
defective cells, suggesting that the resistance to RB-mediated
arrest of these cells is because of a specific defect in RB signaling
to attenuate Cdk2.
Because overexpression of active RB was ineffective at inhib-
iting cell cycle progression in BRG-1-defective cells (Fig. 3B), we
assessed the ability of RB to modulate E2F and cyclin A
promoter activity in SW13 cells (Fig. 3C). To do so, SW13 cells
were cotransfected with either empty vector or PSM-RB and the
E2FyLuc reporter plasmid. These experiments revealed that
active RB inhibited E2F transcriptional activity by 62% when
compared with vector (Left). These data demonstrate that
inhibition of E2F is insufficient to cause RB-mediated arrest and
are consistent with our previous observations (Fig. 2D). Because
we have observed that cyclin A and Cdk2 expression is attenu-
ated in cells arrested by RB, we determined whether RB could
signal to cyclin A in SW13 cells. Cotransfection of either empty
vector or PSM-RB with 2608CycAyLuc into SW13 cells re-
vealed that RB signaling to cyclin A was abrogated, as evidenced
by the inability of active RB to attenuate cyclin A promoter
activity. To verify this effect at the level of protein, SW13 and
PC-3 cells (as a positive control for RB arrest) were cotrans-
fected with empty vector, p16ink4a, or PSM-RB and a vector
carrying puromycin resistance. Transfected cells were rapidly
selected with puromycin, harvested, and immunoblotted for
endogenous cell cycle components. As expected, PC-3 cells
transfected with p16inka demonstrate underphosphorylated RB
and reduced cyclin A and Cdk2 proteins levels, whereas levels of
Cdk4 remained unchanged (Fig. 3D Left). Although the endog-
enous RB was underphosphorylated in p16ink4a-transfected
SW13 cells, no alteration in cyclin A or Cdk2 protein levels was
observed (Fig. 3D Right). These data demonstrate that RB does
not signal to Cdk2ycyclin A in BRG-1-deficient SW13 cells.
In an attempt to restore RB signaling to cyclin A, expression
plasmids encoding BRG-1 and PSM-RB were cotransfected with
2608CycAyLuc into SW13 cells, and the ability of PSM-RB to
signal to the cyclin A promoter was assessed by reporter assay
(Fig. 4A). Although PSM-RB alone did not affect cyclin A
promoter activity, coexpression of BRG-1 and PSM-RB resulted
in an 83% decrease in cyclin A transcriptional activity when
Fig. 3. BRG-1 deficiency renders tumor cell lines resistant to RB-mediated signaling and arrest. (A) Thirty micrograms of total protein from MCF-7, PANC-1, U87,
SW13, PC3, C33A, SAOS-2, U2OS, and RD was separated by 7.5% SDSyPAGE and immunoblotted for BRG-1 and actin. (B) MCF-7, PANC-1, SW13, U87, PC3, C33A,
SAOS-2, U2OS, and RD were cotransfected with GFP expression plasmid and either vector or PSM-RB. Cells were labeled with BrdUrd, and the percentage of
inhibition of BrdUrd incorporation by PSM-RB relative to vector is reported. The data for MCF7, U87, PC3, RD, and U2OS have been previously published (25) and
are shown for illustrative purposes. (B) SW13 cells were cotransfected with H2B-GFP expression plasmid and plasmids encoding vector, PSM-RB, p16ink4a, or
p27Kip1. Cells were labeled with BrdUrd, and the percentage of transfected cells incorporating BrdUrd is shown. (C) SW13 cells were transfected with E2FyLuc,
CMV-b-gal, and PSM-RB plasmids. SW13 cells were also transfected with the cyclin A promoter reporter plasmid 2608Luc, CMV-b-gal, and PSM-RB. (D) SW13 and
PC3 cells were cotransfected with either vector, p16ink4a, or PSM-RB along with pBabe-PURO. Twenty-four hours after transfection, cells were subjected to
puromycin selection. Selected cells were harvested, and equal total protein was resolved by SDSyPAGE and then subjected to immunoblot analysis for RB, cyclin
A, Cdk2, cyclin E, and Cdk4 protein.








compared with vector-transfected cells. Next, we verified this
finding by examining the protein expression of endogenous cell
cycle targets. To do this, SW13 cells were transfected with either
vector, BRG-1, or PSM-RB 1 BRG-1 along with a puromycin
resistance plasmid (Fig. 4B). After rapid selection, the trans-
fected cells were harvested and subjected to immunoblot anal-
ysis. Ectopic expression of BRG-1 alone had little effect on
endogenous cyclin A, Cdk2, or Cdk4, whereas expression of
PSM-RB 1 BRG-1 was sufficient to attenuate cyclin AyCdk2
protein levels without affecting Cdk4 or cyclin E (data not
shown) (Fig. 4B). These data indicate that coexpression of
BRG-1 restores RB signaling to cyclin A in SW13 cells. To
determine whether BRG-1 restores cell cycle arrest, SW13 cells
were cotransfected with plasmids encoding H2B-GFP and either
PSM-RB, BRG-1, or both, and were scored for the ability of the
transfected cells to incorporate BrdUrd. Cells transfected either
with vector, BRG-1, p16ink4a, or PSM-RB alone incorporated
BrdUrd at approximately equal rates (Fig. 4C). However, co-
transfection of BRG-1 and either p16ink4a or PSM-RB resulted
in a significant decrease in cell cycle progression. These findings
indicate that the ability of BRG-1 to mediate RB signaling to
cyclin AyCdk2 is required for the antiproliferative action of RB.
Expression of Dominant-Negative BRG-1 Reverses RB-Mediated Cell
Cycle Arrest. The data presented correlate BRG-1 expression
with the ability of RB to signal to cyclin A and cause cell cycle
arrest. To determine directly whether the antiproliferative action
of RB requires BRG-1, NIH 3T3 cells, which exhibit tetracycline-
regulated expression of dominant-negative BRG-1 (B05–1),
were used (33). On removal of tetracycline from the culture
media, the expression of dnBRG-1 was induced (Fig. 5A). The
B05–1 cells cultured in either the presence or absence of
tetracycline were cotransfected with plasmids encoding H2B-
GFP and either p16ink4a or PSM-RB and were monitored for
the ability to incorporate BrdUrd (Fig. 5B). In the presence of
tetracycline, ectopic expression of p16ink4a and PSM-RB inhib-
ited BrdUrd incorporation by 73% and 81%, respectively (Fig.
5B Left). By contrast, ectopic expression of p16ink4a and
PSM-RB did not significantly inhibit BrdUrd incorporation in
the absence of tetracycline (presence of dnBRG-1) (Fig. 5B
Right). Therefore, these data demonstrate that active BRG-1 is
required for RB-mediated cell cycle arrest.
Ectopic expression of p16ink4a and PSM-RB is known to
mimic the physiological activation of endogenous RB (3, 21). To
determine whether BRG-1 is required for RB-dependent cell
cycle inhibition mediated by a physiological stress, we explored
the response of the B05–1 cells to the DNA-damaging agent
cisplatin (CDDP). It has previously been shown that RB is
required for the cell cycle inhibitory response to CDDP, and that
the activation of RB by CDDP leads to an RB-dependent
reduction in cyclin A expression (40, 41). In the presence of
tetracycline, the expression of dnBRG-1 is repressed, and treat-
ment with 32 mM CDDP resulted in the inhibition of BrdUrd
incorporation (Fig. 5C Left). In contrast, in the absence of
tetracycline, where dnBRG-1 expression was induced, treatment
with 32 mM CDDP had minimal effect on BrdUrd incorporation.
This result was virtually identical to what is observed in Rb2y2
cells, which fail to respond to this dose of CDDP (not shown and
ref. 40). Analysis of the degree of platinated DNA was carried
out with the ICR4 antibody (42), which recognizes platinum-
DNA adducts (Fig. 5C Center) and no significant difference
detected. Thus the observed failure to arrest was not because of
differential repair of the CDDP damage. Lastly, to address the
mechanism through which dnBRG-1 bypasses CDDP-mediated
cell cycle inhibition, cyclin A and Cdk4 protein levels were
monitored (Fig. 5C Right). These results showed that CDDP
leads to the down-regulation of cyclin A expression only in the
absence of dnBRG-1. Collectively, these data indicate that
RB-dependent signaling and cell cycle inhibition achieved
through a physiological stress also depend on BRG-1.
Discussion
In cancer cells, it is known that RB is inactivated via deregulation
of upstream signaling that occurs through either loss of p16ink4a
Fig. 4. BRG-1 expression restores RB-mediated arrest in BRG-1 deficient cells.
(A) SW13 cells were cotransfected with the 2608Luc, CMV-b-gal, and vector,
PSM-RB or PSM-RB 1 BRG-1. Samples were then processed for luciferase
activity and normalized to b-gal activity. (B) SW13 cells were cotransfected
with either vector, BRG-1, or PSM-RB 1 BRG-1 along with pBabe-PURO.
Transfected cells were selected with puromycin, and protein lysates were
resolved by SDSyPAGE and subjected to immunoblotting for cyclin A, Cdk2
and Cdk4. (C) SW13 cells were cotransfected with either vector, p16ink4a,
PSM-RB, BRG-1, p16ink4a 1 BRG-1, or PSM-RB 1 BRG-1 and H2B-GFP expres-
sion plasmids. Cells were labeled with BrdUrd, and the percent of transfected
cells incorporating BrdUrd is shown.
Fig. 5. Expression of dominant-negative BRG-1 prevents RB-mediated ar-
rest. (A) B05-1 cells were cultured in either the absence or presence of 2 mgyml
tetracycline. Cells were harvested, equal total protein was resolved by
SDSyPAGE, and dnBRG-1 protein was detected by anti-FLAG immunoblotting.
(B) B05–1 cells cultured in the absence or presence of tetracycline were
cotransfected with either vector, PSM-RB, or p16ink4a expression plasmids
and the H2B-GFP expression plasmid. Cells were labeled with BrdUrd and
stained for the incorporation of BrdUrd. (C) B05–1 cells cultured in either the
absence or presence of tetracycline were treated with 0 or 32 mM CDDP for
16 h. (Left) Cells were then labeled with BrdUrd for 5 h, at which point they
were fixed and stained for BrdUrd incorporation. (Center) Cells were fixed and
stained for platinated DNA with the ICR4 antibody. Shown are photomicro-
graphs taken at equivalent exposures. (Right ) Cells were lysed, and equal total
protein was resolved by SDSyPAGE. Cyclin A and Cdk4 protein levels were
determined by immunoblotting.
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or overproduction of Cdk4 or cyclin D1 (1–4). The overproduc-
tion of Cdk4ycyclin D (as occurs through gene amplification and
other mechanisms) or loss of p16ink4a each result in deregulated
RB phosphorylation. This leads to the disruption of RB protein
binding and transcriptional repression activity (1–4). Here we
show that BRG-1 deficiency bypasses cell cycle inhibition elicited
by activation of the RB pathway. PSM-RB and p16ink4a fail to
initiate cell cycle arrest in BRG-1-deficient cells (SW13, C33A,
and PANC-1) or in cells harboring a dominant-negative mutant
of BRG-1. Similarly, disruption of BRG-1 abrogated the RB-
dependent cell cycle inhibition after CDDP treatment. Together,
these results indicate that disruption of the RB pathway also
occurs downstream of RB through the loss of a critical factor
required for RB-mediated transcriptional repression.
The mechanism underlying the loss of BRG-1 protein in tumor
cells is not understood. The gene for BRG-1 has not been found
to be deleted in C33A, PANC-1, or SW13 cells, and it is possible
to detect a low level of BRG-1 protein in PANC-1 and C33A cells
(30, 31, 43). This suggests that mechanisms other than genetic
loss are responsible for the attenuated expression of BRG-1 in
these cell lines. All studies carried out to date indicate that
BRG-1 is required for cellular viability (44). This suggests that
genetic loss of BRG-1 would be selected against, whereas
alternative mechanisms to lower the amount of BRG-1 and thus
disrupt its ability to function in the RB-pathway would be
selected for.
Transcriptional repression by RB involves transcription fac-
tors such as E2F (1–4). The recruitment of histone deacetylases
is believed to be the mechanism through which RB leads to
transcriptional repression (12, 13). On the basis of our obser-
vations, we conclude that although this simple description is
sufficient to describe RB-mediated repression of E2FyLuc, it
may not accurately describe how RB mediates the repression of
the cyclin A promoter. Although BRG-1 is known to enhance
RB function as an inhibitor of E2F-mediated transcription (31),
our data indicate that BRG-1 is required for RB to inhibit both
endogenous cyclin A protein expression and cyclin A promoter
activity. Currently, it is unclear how BRG-1 functions to assist
RB-mediated repression. BRG-1 is a member of the mammalian
SWIySNF complex, which has ATP-dependent chromatin re-
modeling capabilities (28, 29). The dnBRG-1 allele used in this
study is specifically defective in ATPase activity, suggesting that
the inactivation of the SWIySNF complex renders cells resistant
to RB-mediated growth inhibition. Therefore, loss of other
members of this complex such as SNF5yBaf47yINI1, which is
lost in rhabdoid tumors, may also disrupt RB function (43, 45).
Disruption of the RB growth inhibitory pathway has been
postulated to occur in virtually all tumors (3, 14). Although cyclin
D, Cdk4, p16ink4a, and RB are lost in a large fraction of human
tumors, additional lesions that disrupt RB signaling are likely
involved in those tumors that do not exhibit mutationyderegu-
lation of any of these proteins. This study shows that loss of
BRG-1 disrupts the ability of RB to signal and is therefore
analogous to RB loss. As such, we demonstrate a mechanism
through which RB is disrupted in cancer via the abolition of
RB-dependent signaling.
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